← SynDRA
ERTUGLIFLOZIN
SynDRA canonical compound SYN0026866 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | SLC5A2 |
|---|
| Mechanism of action | sodium/glucose cotransporter inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
- SLC5A2
- SLC5A1
- SLC5A4
- Slc5a2
Mechanisms of action (all sources)
- SLC5A2 INHIBITOR
- Sodium/glucose cotransporter 2 inhibitor
- sodium/glucose cotransporter inhibitor
- SLC5A2 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- AURKA
- BRD4
- BRPF1
- CDK2
- CSNK1D
- FGFR2
- GSK3B
- HDAC6
- MAPK1
- SLC22A2
- SLC22A6
- SLC22A8
- TRIM24
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Hypoglycemic Agents
- Sodium-Glucose Transporter 2 Inhibitors
ATC classes
- A10B · BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Cross-references
Synonyms
- SEGLUROMET
- STEGLATRO
- STEGLUJAN
- Steglatro
- PF-04971729-00
- steglatro
- ertugliflozin L-pyroglutamic acid
- PF-04971729
- ERTUGLIFLOZINE
- ERTUGLIFLOZINA
- CHEMBL1770248
- MK-8835
- PF04971729
- PF 04971729
- UNII-6C282481IP
- 6C282481IP
- AK174928
- Ertugliflozin [USAN:INN]
- C22H25ClO7
- PF-4971729
- SGLT2 inhibitor (oral, type 2 diabetes), Pfizer
- Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer
- Ertugliflozin/PF-04971729
- PF 04971729-00
- ertugliflozina
- ertugliflozine
- ertugliflozinum
- RefChem:56924
- DTXCID4075611
- A10BK04
- MFCD21609259
- Ertugliflozin (PF 04971729)
- Ertugliflozin (Standard)
- ERTUGLIFLOZIN [MI]
- ERTUGLIFLOZIN [INN]
- Ertugliflozin (USAN/INN)
- ERTUGLIFLOZIN [USAN]
Reported adverse events
- Thirst
- Urinary tract infection
- Back pain
- Headache
- Ketoacidosis
- Nasopharyngitis
- Phimosis
- Pyelonephritis
- Weight
- Weight decreased
- Urosepsis
- Arthralgia
Look up ERTUGLIFLOZIN in the interactive SynDRA portal →